All In Biotech

Investigational drug · Phase 2

Flu mRNA

Also called: GSK6479720A, GSK6498032A, GSK6479715A

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Influenza, Human.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

0 still active

All registered trials

65

Any phase or sponsor naming "Flu mRNA"

First trial start

2025

Aug 25, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Flu mRNA", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Influenza, Human

Approved drugs for the same conditions: Influenza · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "Flu mRNA" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Influenza, Human

  • GP681Phase 32 trials

    Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza

  • GP681 SimulantPhase 32 trials

    Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza

  • ARCT-2304Phase 21 trial

    Arcturus Therapeutics, Inc. · Influenza, Human

  • DL001ZF2G22B, F2H23HPhase 21 trial

    GSK · Influenza, Human

  • DL001Z-NHF2H23D, F2H23BPhase 21 trial

    GSK · Influenza, Human

  • GSK5800544APhase 21 trial

    GSK · Influenza, Human

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.